CNSide Diagnostics

With licensure now in 48 states, continues to advance reliable insight for clinicians managing complex CNS cancers. This expansion marks another step toward making high-precision CSF analysis accessible where it’s needed most.

We’re committed to supporting providers with data that helps inform faster, clearer decisions for their patients with Leptomeningeal Metastases.

More about CNSide and Leptomeningeal Metastases at https://hubs.la/Q03XRhlD0.
Press Release: https://hubs.la/Q03XRh4L0

Visit at Booth 1444 during San Antonio Breast Cancer Symposium to learn how our CSF-based tumor cell analysis is helping clinicians gain deeper clarity in the management of leptomeningeal metastases.

Our team will be onsite to walk through the CNSide® platform, sample workflow, and the latest clinical insights driving more informed decision-making for patients with CNS involvement.

You can also connect with us anytime at https://hubs.la/Q03XLYGr0

Great discussion, and an important look at how integrated and therapeutic can reshape the management of complex CNS . is proud to support this mission with actionable CSF-based insights for patients and clinicians.

Learn more: cnside-dx.com

Dr. Marc Hedrick, MD - CEO, Plus Therapeutics - Radiotherapeutics For Difficult-To-Treat CNS Cancers Dr. Marc Hedrick, MD is President and CEO of Plus Therapeutics, Inc. ( https://plustherapeutics.com/ ), a U.S. clinical-stage pharmaceutical company, focused...

BREAKING NEWS: CNSide® CSF Assay is Now Covered by Humana

We’re proud to share that has entered into a national agreement with Humana (NYSE: HUM), covering approximately 16 million people throughout the U.S., expanding access to the ® Cerebrospinal Fluid Tumor Cell Enumeration test.

This milestone brings CNSide CSF TCE LDT total policy coverage to 67 million people.

Press Release: https://lnkd.in/giMbcEmU

Join our Interest List: https://lnkd.in/g6wktSG8

announces that it has signed a national agreement with Humana, (NYSE: HUM), covering approximately 16 million people throughout the US, to provide the CNSide Diagnostics' Cerebrospinal Fluid Tumor Cell Enumeration lab developed test. This brings CNSide’s® total policy coverage to 67 million people.

Full press release here: bit.ly/4rsk7YP

More about here: cnside-dx.com

Q&A: Metastatic cancer assay for ‘getting people answers’ In August, Plus Therapeutics announced the launch of the CNSide diagnostic platform, a proprietary, highly sensitive, cerebrospinal fluid (CSF) assay platform performed in a Clinical Laboratory Improvement Amendment accredited laboratory.The platform aims to provides healthcare professionals with ac...

will present three clinical data updates at the / Society for NeuroOncology’s Meeting this week.

If you’re attending, be sure to stop by CNSide Diagnostics' booth ( #315) and the booth ( #317) to learn more about our latest advancements in .

CNSide Diagnostics is rapidly expanding its clinical capabilities, national coverage, and scientific footprint.

Stay connected with our latest news, milestones, and diagnostic innovations by joining our email update list.

Subscribe for CNSide updates: https://hubs.la/Q03TmBcc0

Our lab team brought some Halloween fun to the new CNSide Houston facility! We’re thrilled to continue building momentum in our new space as we expand diagnostic capabilities and grow our mission to improve care for patients with central nervous system cancers.

More about our new facility: https://hubs.la/Q03R6YmW0

More about our team: https://hubs.la/Q03R6TXm0

CNSide Diagnostics would like to highlight a new hire, Nikki Taylor - Inside Sales Representative. Congratulations and welcome to the team Nikki!

CNSide Diagnostics is proud to see continued progress across operations and leadership as we work to scale access to our CNSide® Cerebrospinal Fluid (CSF) Assay Platform for patients with leptomeningeal metastases.

Learn more about our platform and join our email list at cnside-dx.com

announces continued operational ex*****on and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostics' Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT).

Recent accomplishments include expansion of the manufacturing footprint, advancements in commercial readiness and appointments in key leadership positions to propel the CNSide diagnostic business forward.

Read more here: bit.ly/42NSCya

More on CNSide here: cnside-dx.com

Leptomeningeal disease (LMD) happens when cancer cells spread to the coating of the brain and spinal cord—but it’s often missed or misunderstood. In this clip, Dr. Seema Nagpal of Stanford Health Care explains what LMD is, how it affects the body, and why improved cancer treatments are helping doctors detect it more often. Watch now to learn the signs, the challenges, and the hope behind earlier diagnosis. #LMD #Leptomeningeal #LungCancerAwareness #EducationIsEmpowerment #LiveLung

When new symptoms appear, don’t be afraid to speak up. Dr. Seema Nagpal of Stanford Health Care explains why MRI results can sometimes be misleading — and why asking for additional tests, like a lumbar puncture, can make all the difference. Watch now: how to advocate for yourself when you’re not being heard. #LungCancer #PatientAdvocacy #EducationIsEmpowerment #LiveLung #LeptomeningealDisease